NCT01290731 - A Study of TMC435 in Genotype 1, Hepatitis C-infected Patients Who Relapsed After Previous Interferon (IFN)-Based Therapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

August 31, 2012

Study Completion Date

August 31, 2012

Conditions

Hepatitis C, Chronic

Interventions

DRUG

TMC435

100-mg capsule once daily for 12 weeks

DRUG

Pegylated interferon (pegIFN alpha-2a)

180 mcg injected subcutaneously (by a syringe under the skin) once weekly for 12 to 36 weeks (or until Week 48).

DRUG

Ribavirin (RBV)

200-mg tablets (daily dose: 600-1000 mg) taken orally (by mouth) two times a day for 12 to 36 weeks (or until Week 48).

Trial Locations (10)

Hiroshima

Ichikawa

Kagoshima

Matsumoto

Musashino

Ohmura

Osaka

Sapporo

Suita

Touon